Unknown PHASE2 INTERVENTIONAL 2-arm NCT02607215

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

Platinum Retreated in Second- or Third-line Patients With Platinum Sensitive Metastatic Triple Negative Breast Cancer (Randomised, Phase II, NPN Trial)

Sponsor: Fudan University

Conditions Metastatic Breast Cancer

Interventions DDP Vinorelbine

Updated 9 times since 2017 Last updated: Apr 19, 2022 Started: Nov 30, 2015 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02607215, this PHASE2 trial focuses on Metastatic Breast Cancer and remains ongoing. Sponsored by Fudan University, it has been updated 9 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
May 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
May 2022 — May 2024 [monthly]

Recruiting PHASE2

Status: Unknown Status → Recruiting
Oct 2021 — May 2022 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 4 earlier versions

Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Mar 2019 — Jan 2021 [monthly]

Recruiting PHASE2
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China